Nature Medicine

Nature Medicine (commonly abbreviated as Nat. Med.) is a flagship medical journal in Springer Nature's Nature Portfolio. Launched in January 1995 and published monthly, it focuses on translational and clinical research and carries a 2025 impact factor of 52.5.Nature Medicine（常用缩写 Nat. Med.）是 Springer Nature 旗下 Nature Portfolio 的旗舰医学期刊，1995 年 1 月创刊，为月刊，聚焦转化医学与临床研究，2025 年影响因子为 52.5。^[1]

Scope

• Scope: the journal judges translational and clinical research on originality, timeliness and impact on improving human health, spanning new concepts in human biology and disease pathogenesis, new therapeutic modalities and drug development, all phases of clinical work and innovative technologies aimed at improving human health.学科定位： 期刊以原创性、时效性与对改善人类健康的影响为选稿标准，覆盖从人类生物学与疾病发病机制的新概念，到新治疗方式与药物开发、各期临床工作以及旨在改善人类健康的创新技术。
• Topics: disease mechanisms, therapeutic modalities and drug development, phase 1 to 4 clinical trials, observational studies and meta-analyses, biomarkers, public and global health, and preclinical or translational studies accompanied by clinical data.收录主题： 疾病机制研究、治疗手段与药物研发、一至四期临床试验、观察性研究与 Meta 分析、生物标志物、公共与全球健康，以及附带临床数据的临床前与转化研究。
• Article types: original research articles form the core, complemented by commissioned reviews, perspectives and news and comment, with the magazine section edited independently.文章体裁： 以原创研究论文为主体，另设综述、观点与新闻评论等约稿栏目，杂志部分独立编排。
• Publishing model: hybrid, primary research can take either the subscription route or gold OA, while reviews, comments and news content remain subscription-only.出版模式： 混合出版，原创论文可经订阅路线或 Gold OA 路线发表，综述与评论类仅走订阅路线。^[2]
• Indexing and metrics: indexed by MEDLINE and the SCIE, the journal reports a 2025 impact factor of 52.5.收录与指标： 为 MEDLINE 与 SCIE 收录，2025 年影响因子 52.5。^[3]

History

• Founded: launched in January 1995 with the clear objective of giving readers worldwide access to the very best biomedical research together with analysis, news and comment.创刊： 1995 年 1 月创刊，创刊目标是让全球读者读到最优质的生物医学研究以及配套的分析、新闻和评论。
• Founding mission: a 2018 official editorial recalls that the journal began with a broad scope and the bold mission of bridging researchers in the lab and clinicians at the hospital while supporting the emerging discipline of molecular medicine.创办使命： 2018 年官方社论回顾，刊物以宽阔的学科覆盖面为起点，致力于弥合实验室研究者与临床医生之间的鸿沟，并服务于分子医学这一新兴学科。
• Publisher: the journal is published by Nature Portfolio, part of Springer Nature.出版方： 现由 Springer Nature 旗下的 Nature Portfolio 出版。
• Editorial transition: the current chief editor, João Monteiro, took office in December 2017 after serving as a senior editor for immunology and translational medicine at Cell.主编更替： 现任主编 João Monteiro 于 2017 年 12 月上任，此前曾任 Cell 免疫学与转化医学高级编辑。^[4]

Editors

• Editor-in-chief: João Monteiro, MD PhD, trained in the mechanisms of immune tolerance and later at the US National Institutes of Health, where he studied T-cell antigen recognition and the in vivo dynamics of immune responses.现任主编： João Monteiro，医学博士与哲学博士，受过自身免疫耐受机制研究训练，曾赴美国国立卫生研究院研究 T 细胞抗原识别与免疫应答的体内动力学。
• Other editors: deputy editors Liam Messin for global health and public health and Saheli Sadanand for oncology, immunotherapy and rheumatology, alongside senior editors for the magazine, research analysis and research.其他编辑： 副编辑 Liam Messin 负责全球健康与公共卫生，Saheli Sadanand 负责肿瘤、免疫治疗与风湿病学，另设杂志、研究分析与研究等类别的高级编辑。
• Editorial board: there is no external editorial board, all editorial decisions are made by a full-time professional team based in New York, London, Berlin and Shanghai, supported by a statistical advisory panel.编委构成： 不设外部编委会，全部编辑决定由纽约、伦敦、柏林与上海的全职专业编辑团队作出，并设统计顾问小组。
• Submission and review: manuscripts go through Nature's own tracking system, reviewers are anonymous by default, authors may opt for double-anonymized review, and presubmission enquiries are not accepted.投稿与评审： 经 Nature 自建稿件追踪系统投稿，默认审稿人匿名，作者可选择双匿名评审，不接受投稿前咨询。^[5]